Literature DB >> 28123585

Host knockout of E-prostanoid 2 receptors reduces tumor growth and causes major alterations of gene expression in prostaglandin E2-producing tumors.

Annika Gustafsson Asting1, Britt-Marie Iresjö1, Camilla Nilsberth2, Ulrika Smedh1, Kent Lundholm1.   

Abstract

Prostaglandin E2 (PGE2) is elevated in a variety of malignant tumors and has been shown to affect several hallmarks of cancer. Accordingly, the PGE2 receptor, E-prostanoid 2 (EP2), has been reported to be associated with patient survival and reduced tumor growth in EP2-knockout mice. Thus, the aim of the present study was to screen for major gene expression alterations in tumor tissue growing in EP2-knockout mice. EP2-knockout mice were bred and implanted with EP2 receptor-expressing and PGE2-producing epithelial-like tumors. Tumor tissue and plasma were collected and used for analyses with gene expression microarrays and multiplex enzyme-linked immunosorbent assays. Tumor growth, acute phase reactions/systemic inflammation and the expression of interleukin-6 were reduced in EP2-knockout tumor-bearing mice. Several hundreds of genes displayed major changes of expression in the tumor tissue when grown in EP2-knockout mice. Such gene alterations involved several different cellular functions, including stemness, migration and cell signaling. Besides gene expression, several long non-coding RNAs were downregulated in the tumors from the EP2-knockout mice. Overall, PGE2 signaling via host EP2 receptors affected a large number of different genes involved in tumor progression based on signaling between host stroma and tumor cells, which caused reduced tumor growth.

Entities:  

Keywords:  EP2 receptor; EP2-knockout; cancer; cyclooxygenase; prostaglandin E2; tumor growth

Year:  2016        PMID: 28123585      PMCID: PMC5244965          DOI: 10.3892/ol.2016.5448

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Prostaglandin EP2 receptor signalling inhibits the expression of matrix metalloproteinase 13 in human osteoarthritic chondrocytes.

Authors:  Tomoo Sato; Koji Konomi; Ryoji Fujii; Hiroyuki Aono; Satoko Aratani; Naoko Yagishita; Natsumi Araya; Kazuo Yudoh; Moroe Beppu; Yoshihisa Yamano; Kusuki Nishioka; Toshihiro Nakajima
Journal:  Ann Rheum Dis       Date:  2010-09-24       Impact factor: 19.103

2.  Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis.

Authors:  Robert L Keith; Mark W Geraci; S Patrick Nana-Sinkam; Richard M Breyer; Tyler M Hudish; Amy M Meyer; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

3.  Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells.

Authors:  Maria S Pino; Steffan T Nawrocki; Francesco Cognetti; James L Abruzzese; Henry Q Xiong; David J McConkey
Journal:  Cancer Biol Ther       Date:  2005-12-01       Impact factor: 4.742

4.  Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis.

Authors:  Jun-Yang Liou; David P Ellent; Sang Lee; Jennifer Goldsby; Bor-Sheng Ko; Nena Matijevic; Jaou-Chen Huang; Kenneth K Wu
Journal:  Stem Cells       Date:  2007-01-18       Impact factor: 6.277

5.  Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype.

Authors:  L Bastien; N Sawyer; R Grygorczyk; K M Metters; M Adam
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

Review 6.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

7.  Genomic responses in mouse models poorly mimic human inflammatory diseases.

Authors:  Junhee Seok; H Shaw Warren; Alex G Cuenca; Michael N Mindrinos; Henry V Baker; Weihong Xu; Daniel R Richards; Grace P McDonald-Smith; Hong Gao; Laura Hennessy; Celeste C Finnerty; Cecilia M López; Shari Honari; Ernest E Moore; Joseph P Minei; Joseph Cuschieri; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Marc G Jeschke; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Bernard H Brownstein; Carol Miller-Graziano; Steve E Calvano; Philip H Mason; J Perren Cobb; Laurence G Rahme; Stephen F Lowry; Ronald V Maier; Lyle L Moldawer; David N Herndon; Ronald W Davis; Wenzhong Xiao; Ronald G Tompkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Authors:  Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-12-06       Impact factor: 79.321

9.  Forces shaping the fastest evolving regions in the human genome.

Authors:  Katherine S Pollard; Sofie R Salama; Bryan King; Andrew D Kern; Tim Dreszer; Sol Katzman; Adam Siepel; Jakob S Pedersen; Gill Bejerano; Robert Baertsch; Kate R Rosenbloom; Jim Kent; David Haussler
Journal:  PLoS Genet       Date:  2006-08-23       Impact factor: 5.917

10.  Food intake, tumor growth, and weight loss in EP2 receptor subtype knockout mice bearing PGE2-producing tumors.

Authors:  Britt-Marie Iresjö; Wenhua Wang; Camilla Nilsberth; Marianne Andersson; Christina Lönnroth; Ulrika Smedh
Journal:  Physiol Rep       Date:  2015-07
View more
  5 in total

1.  Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors.

Authors:  Pavel V Ershov; Evgeniy O Yablokov; Leonid A Kaluzhskiy; Yuri V Mezentsev; Alexis S Ivanov
Journal:  Biology (Basel)       Date:  2022-04-13

2.  Reduced tumor growth in EP2 knockout mice is related to signaling pathways favoring an increased local anti‑tumor immunity in the tumor stroma.

Authors:  Maria Khan; Cecilia Engström; Johan Bourghardt Fagman; Ulrika Smedh; Kent Lundholm; Britt-Marie Iresjö
Journal:  Oncol Rep       Date:  2022-05-11       Impact factor: 4.136

3.  The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases.

Authors:  Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Theresa Vilsmaier; Lennard Schröder; Bernd P Kost; Julia Gallwas; Udo Jeschke; Sven Mahner; Helene Hildegard Heidegger
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

4.  The role of EP-2 receptor expression in cervical intraepithelial neoplasia.

Authors:  Elisa Schmoeckel; Patricia Fraungruber; Christina Kuhn; Udo Jeschke; Sven Mahner; Theresa Maria Kolben; Thomas Kolben; Theresa Vilsmaier; Anna Hester; Helene Hildegard Heidegger
Journal:  Histochem Cell Biol       Date:  2020-08-26       Impact factor: 4.304

5.  Thymoquinone Suppresses Migration of Human Renal Carcinoma Caki-1 Cells through Inhibition of the PGE2-Mediated Activation of the EP2 Receptor Pathway.

Authors:  Geumi Park; Na-Young Song; Do-Hee Kim; Su-Jun Lee; Kyung-Soo Chun
Journal:  Biomol Ther (Seoul)       Date:  2021-01-01       Impact factor: 4.634

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.